Glucose-Independent Metabolic Signatures of SGLT2 Inhibition in Diabetic Kidney Disease: Integrated Insights from Mendelian Randomization and Transcriptomics.
Background Diabetic kidney disease (DKD) remains a major cause of terminal renal failure, with residual risk remaining unacceptably high despite standard glucose control. Although the sodium-glucose co-transporter 2 (SGLT2) inhibitors have proven reno-protective properties extending beyond that explained by glucose low...